Preprint
Article
Dual-Energy CT Iodine Uptake of Head and Neck: Definition of Reference Values in a Big Data Cohort
Altmetrics
Downloads
82
Views
27
Comments
0
A peer-reviewed article of this preprint also exists.
This version is not peer-reviewed
Submitted:
04 February 2024
Posted:
05 February 2024
You are already at the latest version
Alerts
Abstract
Abstract
Purpose
Despite a considerable amount of literature on dual-energy-CT(DECT) iodine uptake of the head and neck, the physiologic iodine uptake of this region has not been defined yet. This study aims to establish reference values for the iodine uptake of healthy organs to facilitate clinical application.
Material and Methods:
Consecutive venous DECT scans of head and neck were reviewed, and unremarkable exams were included (n=617). 35 region of interest measurements were performed in 16 anatomical regions. Iodine uptake was compared among different organs/tissues and subgroup analysis was performed (male [n=403] vs female [n=214]; young [n=207] vs middle-aged [n=206] vs old [n=204]; normal weight [n=314] vs overweight [n=196] vs obese [n=107]]).
Results:
Overall mean iodine uptake values ranged between 0.5 and 9.4mg/ml. Women showed higher iodine concentration in the cervical vessels and higher uptake for the parotid gland, masseter muscle, submandibular glands, sublingual glands, palatine tonsils, tongue body, thyroid gland, and the sternocleidomastoid muscle than men (p0.04). With increasing age, intravascular iodine concentrations increased as well as iodine uptake for cerebellum and thyroid gland, while values for tongue and palatine tonsils were lower compared to younger subjects (p0.03). Iodine concentrations for parotid glands and sternocleidomastoid muscles decreased with higher BMI (p0.004), while normal-weighted patients showed higher iodine values inside the jugular veins, other cervical glands, and tonsils versus patients with higher BMI (p0.04).
Conclusion:
Physiologic iodine uptake values of cervical organs and tissues show gender-, age-, and BMI-related differences, which should be considered in clinical routine of head and neck DECT.
Keywords:
Subject: Medicine and Pharmacology - Other
1. Introduction
CT imaging of the head and neck region has a central role in the diagnosis of acute and non-acute inflammatory processes, trauma, and malignancies. Due to its widespread availability and low costs compared to MRI, contrast-enhanced CT is frequently the first imaging method of choice used to obtain the necessary information in this complex anatomical region, despite its inferiority in soft tissue visualization.
However, following technological advances in dual-energy CT (DECT), CT-based diagnostics can be significantly enhanced and refined [1,2]. Courtesy of the dual-energy technology and the resulting sophisticated material decomposition analysis, virtual maps of the iodine uptake of tissues can be reconstructed and absolute values [in mg/ml] can be obtained, presenting a highly accurate, novel quantitative parameter [3,4,5,6,7,8,9].
Despite the extensive interest in utilizing iodine values as a measurable biomarker in abdominal CT – mainly to differentiate between benign and malignant lesions or quantitative perfusion analyses – there is hardly any application in the field of head and neck imaging. The limited experience with the methodology in this small anatomical region with multiple organs and, above all, the lack of reference values may be the major restraints.
To facilitate future clinical use, this study aimed to define and establish reference values for the iodine uptake of healthy head and neck organs and important anatomical landmarks.
2. Materials and Methods
2.1. Study population
After approval of our monocentric, retrospective study by our institutional review board, we performed an analysis of our database for patients who had undergone clinically indicated, contrast-enhanced DECT scans of the head and neck region between December 2016 and December 2020 with no pathologies detectable in CT imaging (scans were performed in clinical routine, e.g., after trauma, to exclude infections or tumors, or to exclude cervical lymphadenopathies and other suspected cervical pathologies). Absence of pathologies was carefully confirmed by two independent radiologists before inclusion. Common laboratory values of all patients were within the normal range. None of the subjects had a history of known head/neck surgery, malignancy, or other known diseases. In a follow-up period of one year, none of the patients showed cervical symptomatology (confirmed by anamnestic interviews, clinical examinations, ultrasound examinations, or cross-sectional imaging). Further exclusion criteria were patients younger than 18 years, imaging artifacts, and patients with systemic treatment. Figure 1 depicts the flowchart of patient inclusion.
2.2. DECT imaging technique
All examinations were performed on the same third-generation dual-energy CT scanner (SOMATOM Force, Siemens Healthcare). Patients were examined in supine position and CT images were acquired from the orbital roofs to the aortic arch. The study protocol consisted of a single venous-phase acquisition in DECT mode, which automatically started 70 s after the beginning of the injection of Iomeprol (Imeron 350, Bracco). Contrast media (1.2 ml/kg body weight) was injected into a superficial vein of the forearm at a flow rate of 3 ml/s. The following parameters were used for DECT imaging: 90 kV and 190 mAs per rotation on tube A, Sn 150 kV with tin filter and 95 mAs per rotation on tube B, 0.5 s rotation time, 0.6 pitch, and 2 × 192 × 0.6 mm collimation. All image series were reconstructed with 3.0-mm slice thickness in a 2.0-mm increment by using a soft-tissue(Bv40) kernel.
2.3. Iodine mapping and uptake measurements
Dual-energy analysis was performed by using the commercially available post-processing software Liver virtual non-contrast (VNC) (syngo.via, Siemens Healthineers). Initially designed for iodine measurements in the liver, the liver VNC software has already been used for measurements in various anatomic regions [4,5,10,11]. Basis of its algorithm is a three-material-decomposition of iodine, fat, and tissue. The liver VNC application enables the visualization of iodine (contrast agent) concentration by decomposing the iodine content out of the Hounsfield unit value of any voxel and displaying the pure iodine map as a colored overlay on the gray-scale image. The iodine slope was calculated automatically by the software at 90 keV and 150 keV. Settings were left on default (Resolution: 2, Maximum [HU]: 3071, Iodine Ratio 3.46).
By performing circular dual-energy region of interest (ROI) measurements on the generated maps, iodine density can be calculated (in mg/ml). The measurements were independently performed by two radiologists (with 6 and 15 years of experience) in all patients and mean values were calculated.
Depending on the size of the organ/region, ROI measurements were targeted to be between 0.4 cm2 and 1.0 cm2 and were carefully placed to avoid the inclusion of surrounding tissue. In total, 35 ROIs were placed in each study by one investigator and the corresponding absolute iodine concentration values for each ROI were extracted. To minimize the influence of patient-specific perfusions on the results, additional bilateral measurements of the intraluminal iodine concentration of the common carotid artery were performed to achieve data normalization by calculating the iodine ratio (absolute iodine concentration of tissue / iodine concentration in common carotid artery). To verify the correctness of the measurements, an additional ROI was placed in an area where iodine uptake was not expected (inside the trachea). A detailed list of the distribution of the measurements can be found in Table 1. Examples of ROI placements are shown in Figure 2.
2.4. Statistical analysis
Mean values were calculated for each organ and structure. For the overall analysis and the subgroup analyses mean values and standard deviations (SD) were calculated. Numerical values of continuous variables were listed as mean values ± standard deviation. Gaussian data distribution was assessed using the Kolmogorov-Smirnov test. Unpaired t–test and analysis of variance (ANOVA) with Tukey multiple comparison post–hoc tests were performed for normally distributed data. Mann-Withney-U test and Kruskal-Wallis tests were applied in case of non-normal distribution. A statistically significant difference was defined by a p-value less than 0.05. Statistical analysis was performed by using GraphPad Prism Version 7.0 (GraphPad Software; La Jolla, CA, USA) and IBM SPSS Statistics Version 28. (IBM SPSS statistics; Armonk, NY, USA).
3. Results
3.1. Patient collective
The final study cohort consisted of 617 patients (caucasian: 596, asian: 13, black: 4, Hispanic: 4; mean age, 55.0 ± 18.1 years; range, 18–98 years), including 214 women (mean age, 54.4 ± 18.6 years; range, 18-98 years) and 403 men (mean age, 55.3 ± 17.8 years; range, 18-91 years).
Subgroups were defined regarding sex (male [n = 403] vs. female [n = 214]), age (18-48 [n = 207] vs. 49-64 [n = 206] vs. 65-98 [n = 204] years), and BMI (24.9 or below [n = 314] vs. 25-29.9 [n = 196] vs. 30.0 and above [n = 107] kg/m2).
3.2. Overall iodine values
There were no side differences in the same subjects for paired structures and organs regarding absolute iodine values (p > 0.43). Therefore, mean values were calculated for paired organs/structures.
Besides the contrast-media enhanced jugular vein with 6.66 ± 2.7 mg/ml and the carotid artery with 5.88 ± 2.0 mg/ml, highest absolute iodine concentration values were documented for the thyroid gland with mean values of 4.68 ± 1.5 mg/ml. The temporal lobes with mean values of 0.82 ± 0.4 mg/ml and the neck muscles (sternocleidomastoid: 0.76 ± 0.3 mg/ml and masseter: 0.99 ± 0.4 mg/ml) demonstrated low iodine uptake. The same trend was seen in the normalized iodine ratios. No iodine uptake was recorded in the control measurements inside the trachea (air).
3.3. Impact of sex
Women showed higher iodine concentrations in the carotid artery (6.31 ± 2.1 vs. 5.66 ± 1.8 mg/ml, p < 0.001) and in the jugular vein (7.56 ± 3.1 vs. 6.18 ± 2.3 mg/ml, p < 0.001) as well as higher iodine uptake for all cervical glands: the parotid glands (2.00 ± 0.8 vs 1.76 ± 0.7 mg/ml, p < 0.001), submandibular glands (2.57 ± 1.3 vs. 2.27 ± 1.2 mg/ml, p = 0.004), sublingual glands (3.53 ± 1.0 vs. 3.35 ± 0.9 mg/ml, p = 0.04), and the thyroid glands (5.07 ± 1.6 vs 4.48 ± 1.4 mg/ml, p < 0.001). Furthermore, absolute iodine values for masseter muscles (1.06 ± 0.4 vs. 0.96 ± 0.4 mg/ml, p = 0.003), the tongue (1.52 ± 0.5 vs 1.41 ± 0.5 mg/ml, p = 0.04) and palatine tonsils (1.74 ± 0.7 vs 1.57 ± 0.6 mg/ml, p = 0.02) were higher in women than men.
Regarding iodine ratios, women and men differed in the values for the jugular vein (higher values for women), cerebellum (higher values for men), uvula (higher values for male patients), and sublingual glands (higher ratio for men) (p < 0.05).
3.4. Impact of age
Comparing all three age groups, the greatest differences in absolute values were observed between the youngest and oldest groups. For the carotid artery (5.48 ± 2.0 vs 6.39 ± 2.1 mg/ml, p < 0.001), jugular vein (5.75 ± 1.8 vs 7.48 ± 3.2 mg/ml, p < 0.001), the cerebellum (1.36 ± 0.4 vs 1.45 ± 0.3 mg/ml, p = 0.02), and thyroid gland (4.10 ± 1.2 vs 5.18 ± 1.7 mg/ml, p < 0.001) older patient showed higher values than the young group, while being lower for the masseter muscle (1.06 ± 0.4 vs 0.91 ± 0.4 mg/ml, p < 0.001), palatine tonsils (1.74 ± 0.7 vs 1.57 ± 0.6 mg/ml, p = 0.03), and lingual tonsil (1.24 ± 0.4 vs 1.13 ± 0.5 mg/ml, p = 0.02). Fewer significant differences can be reported between the young and middle-aged groups (carotid artery, jugular vein, cerebellum, palatine tonsils, vocal cords, and thyroid gland) (p ≤ 0.03). The closest groups were the middle-aged and old age groups, with only changes in iodine uptake for the masseter muscle (p = 0.009) and thyroid gland (p = 0.01) aside from the cervical vesicles (p ≤ 0.02). However, when normalized iodine ratios were analyzed, the oldest group showed most frequently significant differences and lowest iodine ratios compared to the other age groups (p ≤ 0.03). A detailed demonstration of all data can be found in Table 4 and Figure 5.
3.5. Impact of BMI
The three subgroups defined by BMI showed the least differences in absolute and normalized data (Table 5 and Figure 6).
Absolute iodine concentrations in patients with a normal BMI were higher for the jugular vein (p < 0.001), parotid glands (p < 0.001), sublingual glands (p ≤ 0.02), and the sternocleidomastoid muscle (p < 0.001) when compared to the overweight and obese group. Additionally, the obese group had lower values for palatine tonsils, lingual tonsils, and the thyroid when compared to the group with BMI lower than 25 (p ≤ 0.02). Comparing overweight patients and obese patients, the parotid gland and the lingual tonsils showed a decline with higher BMI (p < 0.004).
Even less differences were documented in the iodine ratios with jugular vein ratio in obese being higher than in normal-weighted patients (p = 0.02), parotid glands showing higher iodine values for normally weighted patients (vs overweight and obese) (p ≤ 0.003), and the sternocleidomastoid muscle having a lower iodine perfusion for overweight and obese, when compared to normally weighted patients (p ≤ 0.004).
4. Discussion
As the very first study, we investigated the iodine concentration of cervical organs and anatomical structures to define physiologic reference values for the iodine uptake of healthy head and neck organs and tissues in a big data cohort. As indicated by DECT iodine maps, we measured absolute iodine concentrations and normalized iodine ratios for 16 structures in head and neck CT scans and identified differences related to age, gender, and weight. Our study results showed that iodine quantification in the selected structures has a wide absolute range between 0.1 mg/ml and 25.1 mg/ml (13.2 mg/ml excluding the cervical vessels). The thyroid gland showed the highest iodine uptake and iodine ratio. Significant differences were noted regarding the iodine distribution of cervical organs concerning sex, age, and BMI.
All cervical glands showed higher absolute uptake in the female body than in men. Also, both investigated muscles showed a higher iodine density in women compared to men. Even though the amount of applied contrast agent was proportioned according to body habitus, a lower amount of contrast agent could potentially be sufficient in women when integrating iodine maps in clinical routine. This could be beneficial in reducing the risk of contrast-induced nephropathy, especially in patients with preexisting kidney diseases and potentially reducing the risk/severity of allergic and anaphylactic reactions to intravascular iodinated contrast media in young females, who have a higher allergic risk compared to males of the same age [12,13,14].
While there is a significant loss of iodine uptake in the masseter muscle and the palatine in the course of aging, an increase in iodine perfusion is noted for the thyroid. A weaker and slower circulation could be the reason for the continuous increase in iodine concentrations in the vessels among young, middle-aged and elderly groups.
Although a higher BMI results in lower iodine values in the parotid gland, there were only limited effects of weight, mainly being between the normal weighted and obese groups (significant differences regarding sublingual gland, palatine tonsil, lingual tonsil, thyroid gland, and sternocleidomastoid muscle). We hypothesized that body habitus affects iodine concentration in various organs and tissues due to differences in tissue composition, metabolic activity, and vascularity. Adipose tissue has a lower blood supply than lean tissue and this could impact the delivery and uptake of iodine.
One fundamental challenge in head and neck imaging for radiologists consists of prompt and accurate detection and interpretation of pathologies. In the last decade, approaches in DECT technology have significantly improved the visualization of tissue alterations and pathologic processes by utilizing material decomposition algorithms to investigate the atomic composition of the tissue and calculate iodine maps. Aside from morphologic, size, and shape changes, iodine quantification has enabled an additional targeted analysis of tissue characteristics and organ perfusion in contrast-enhanced CT images [2]. Lam et al. [15] reported on an improved delineation of tumor edges of squamous cell carcinoma (one of the most common malignancies of the head and neck) on iodine overlay maps [16]. In another study on squamous cell carcinoma, Kuno et al. could significantly increase the specificity of CT in the differentiation between healthy and tumor-infiltrated laryngeal cartilage by application of iodine maps. Furthermore, quantification of iodine concentration introduced a new, highly accurate and reproducible parameter besides Hounsfield units, which are dependent on photon energy levels, mass density, and attenuation coefficient [3,6,17,18,19].
Even though many approaches in abdominal dual-energy CT have already demonstrated that iodine quantification can determine diagnostic thresholds for benign/malignant characterization or various disease states, the application in the head and neck field is still very limited [20,21,22,23]. Up to date literature on DECT application in head and neck imaging is sparse, mostly focusing on categorizing different malignant cervical lymphadenopathies [24]. A study from Sauters et al. – one of the few studies where healthy structures of the head and neck area were analyzed – investigated healthy lymph nodes in the body, including cervical lymph nodes [25]. Their results (n=297) of 2.09 ± 0.44 mg/ml are consistent with our definition for healthy cervical lymph nodes (1.72 ± 1.0 mg/ml). Our study furthermore showed that the cervical glands have a high individual variability in their iodine uptake, which may be due to several factors, for example individual glandular sizes and shapes, glandular function, and iodine uptake kinetics. This underscores the need for further investigations that facilitate a more reliable clinical application of this quantification technique in the head and neck area. In this context, our aim was to enable a more reliable clinical application of this quantification technique and ultimately, potential implementation in future guidelines. Based on the provided data of this study, interpretation of iodine uptake measurements and detection of pathologies in the head and neck region may be potentially optimized.
There are limitations of this study that need to be addressed. Due to biodynamical and size changes with age, not every structure could be included, e.g., pharyngeal tonsils being prominent in younger patient groups and often not measurable in older groups.
We – to the best of our knowledge – excluded all patients with known diseases or pathologies. However, there could be preexisting or specific patient characteristics (like muscle mass, previous meals or muscular activity, and other factors) which might not have been taken into account in this study. For instance, conditions such as hypertension and diabetes can affect the delivery and distribution of contrast media, due to alterations in microvasculature and blood flow patterns. This can lead to alterations in iodine uptake in tissues, but conclusive evidence regarding the impact of these morbidities on DECT iodine uptake is currently lacking.
We would like to clarify that the main focus of our study is on the iodine uptake in the cervical region. Brain structures were included in the analysis because they were in the scan field and constituting part of the imaging datasets. We acknowledge that the inherent nonhomogeneity of the brain structures due to gray and white matter as well as location, and the presence of the blood-brain barrier may affect the iodine uptake.
CT scans, as well as postprocessing, were performed using one manufacturer (Siemens Healthineers), restricting a generalization of our results for other systems. Differences may also occur when different scan and contrast media application protocols are chosen. It should be noted that the presented study was applied on portal venous CT datasets, using different scan phases will cause different outcomes.
In this study, a predominantly Caucasian study population was included, there is a need for more diverse studies to establish more comprehensive referencing. Because no statistical error propagation was performed, the results could have been affected by calculation errors.
5. Conclusion
In conclusion, this study provides reference values of iodine concentration in healthy head and neck structures valid for examinations with a delay of 70 s after injection. The scatter and the differences between sex, age groups, and BMI should be considered when performing iodine measurements. Particularly, care should be taken in interpretation of iodine values in clinical settings.
Abbreviations
| BMI | body mass index |
| CT | computed tomography |
| DECT | dual-energy CT |
| kV | kilovolt |
| mAs | milliampere-seconds |
| MRI | magnetic resonance imaging |
| ROI | region of interest |
References
- Roele, E.D.; Timmer, V.C.M.L.; Vaassen, L.A.A.; van Kroonenburgh, A.M.J.L.; Postma, A.A. Dual-Energy CT in Head and Neck Imaging. Curr Radiol Rep 2017, 5, 19–19. [Google Scholar] [CrossRef] [PubMed]
- Forghani, R. Advanced dual-energy CT for head and neck cancer imaging. Expert Rev Anticancer Ther 2015, 15, 1489–1501. [Google Scholar] [CrossRef] [PubMed]
- Harsaker, V.; Jensen, K.; Andersen, H.K.; Martinsen, A.C. Quantitative benchmarking of iodine imaging for two CT spectral imaging technologies: a phantom study. European Radiology Experimental 2021, 5, 24. [Google Scholar] [CrossRef]
- Martin, S.S.; Weidinger, S.; Czwikla, R.; Kaltenbach, B.; Albrecht, M.H.; Lenga, L.; Vogl, T.J.; Wichmann, J.L. Iodine and Fat Quantification for Differentiation of Adrenal Gland Adenomas From Metastases Using Third-Generation Dual-Source Dual-Energy Computed Tomography. Investigative radiology 2018, 53, 173–178. [Google Scholar] [CrossRef] [PubMed]
- Martin, S.S.; Trapp, F.; Wichmann, J.L.; Albrecht, M.H.; Lenga, L.; Durden, J.; Booz, C.; Vogl, T.J.; D’Angelo, T. Dual-energy CT in early acute pancreatitis: improved detection using iodine quantification. Eur Radiol 2019, 29, 2226–2232. [Google Scholar] [CrossRef]
- Pelgrim, G.J.; van Hamersvelt, R.W.; Willemink, M.J.; Schmidt, B.T.; Flohr, T.; Schilham, A.; Milles, J.; Oudkerk, M.; Leiner, T.; Vliegenthart, R. Accuracy of iodine quantification using dual energy CT in latest generation dual source and dual layer CT. European radiology 2017, 27, 3904–3912. [Google Scholar] [CrossRef]
- Lenga, L.; Bernatz, S.; Martin, S.S.; Booz, C.; Solbach, C.; Mulert-Ernst, R.; Vogl, T.J.; Leithner, D. Iodine Map Radiomics in Breast Cancer: Prediction of Metastatic Status. Cancers (Basel) 2021, 13. [Google Scholar] [CrossRef]
- Kim, Y.S.; Kim, S.H.; Ryu, H.S.; Han, J.K. Iodine Quantification on Spectral Detector-Based Dual-Energy CT Enterography: Correlation with Crohn’s Disease Activity Index and External Validation. Korean J Radiol 2018, 19, 1077–1088. [Google Scholar] [CrossRef] [PubMed]
- Patel, B.N.; Vernuccio, F.; Meyer, M.; Godwin, B.; Rosenberg, M.; Rudnick, N.; Harring, S.; Nelson, R.; Ramirez-Giraldo, J.C.; Farjat, A.; et al. Dual-Energy CT Material Density Iodine Quantification for Distinguishing Vascular From Nonvascular Renal Lesions: Normalization Reduces Intermanufacturer Threshold Variability. AJR. American journal of roentgenology 2019, 212, 366–376. [Google Scholar] [CrossRef]
- Zhang, C.; Wang, N.; Su, X.; Li, K.; Yu, D.; Ouyang, A. FORCE dual-energy CT in pathological grading of clear cell renal cell carcinoma. Oncol Lett 2019, 18, 6405–6412. [Google Scholar] [CrossRef]
- Yan, W.Q.; Xin, Y.K.; Jing, Y.; Li, G.F.; Wang, S.M.; Rong, W.C.; Xiao, G.; Lei, X.B.; Li, B.; Hu, Y.C.; et al. Iodine Quantification Using Dual-Energy Computed Tomography for Differentiating Thymic Tumors. Journal of computer assisted tomography 2018, 42, 873–880. [Google Scholar] [CrossRef]
- Lasser, E.C. Second Harry Fischer Lecture. Sex, surfaces, sulfation, and sensitivity. Investigative radiology 1991, 26 (Suppl. 1), S16–19. [Google Scholar] [CrossRef]
- Lasser, E.C.; Berry, C.C.; Talner, L.B.; Santini, L.C.; Lang, E.K.; Gerber, F.H.; Stolberg, H.O. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N Engl J Med 1987, 317, 845–849. [Google Scholar] [CrossRef]
- Klostranec, J.M.; Rohringer, T.; Gerber, R.; Murphy, K.J. The Role of Biologic Sex in Anaphylactoid Contrast Reactions: An Important Consideration for Women of Reproductive Age and Undergoing Hormone Replacement Therapy. Radiology 2021, 299, 272–275. [Google Scholar] [CrossRef]
- Lam, S.; Gupta, R.; Kelly, H.; Curtin, H.D.; Forghani, R. Multiparametric Evaluation of Head and Neck Squamous Cell Carcinoma Using a Single-Source Dual-Energy CT with Fast kVp Switching: State of the Art. Cancers (Basel) 2015, 7, 2201–2216. [Google Scholar] [CrossRef] [PubMed]
- Chi, A.C.; Day, T.A.; Neville, B.W. Oral cavity and oropharyngeal squamous cell carcinoma--an update. CA Cancer J Clin 2015, 65, 401–421. [Google Scholar] [CrossRef]
- Große Hokamp, N.; Abdullayev, N.; Persigehl, T.; Schlaak, M.; Wybranski, C.; Holz, J.A.; Streichert, T.; Alkadhi, H.; Maintz, D.; Haneder, S. Precision and reliability of liver iodine quantification from spectral detector CT: evidence from phantom and patient data. European radiology 2019, 29, 2098–2106. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Wagner-Bartak, N.; Jensen, C.T.; Hui, A.; Wei, W.; Lertdilok, P.; Qayyum, A.; Tamm, E.P. Dual-energy CT of pancreatic adenocarcinoma: reproducibility of primary tumor measurements and assessment of tumor conspicuity and margin sharpness. Abdominal Radiology 2016, 41, 1317–1324. [Google Scholar] [CrossRef]
- Li, J.-H.; Du, Y.-M.; Huang, H.-M. Accuracy of dual-energy computed tomography for the quantification of iodine in a soft tissue-mimicking phantom. Journal of Applied Clinical Medical Physics 2015, 16, 418–426. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Yan, F.; Pan, Z.; Lin, X.; Luo, X.; Shi, C.; Chen, X.; Wang, B.; Zhang, H. Evaluation of dual energy spectral CT in differentiating metastatic from non-metastatic lymph nodes in rectal cancer: Initial experience. European journal of radiology 2015, 84, 228–234. [Google Scholar] [CrossRef] [PubMed]
- Mileto, A.; Marin, D.; Alfaro-Cordoba, M.; Ramirez-Giraldo, J.C.; Eusemann, C.D.; Scribano, E.; Blandino, A.; Mazziotti, S.; Ascenti, G. Iodine Quantification to Distinguish Clear Cell from Papillary Renal Cell Carcinoma at Dual-Energy Multidetector CT: A Multireader Diagnostic Performance Study. Radiology 2014, 273, 813–820. [Google Scholar] [CrossRef] [PubMed]
- Zarzour, J.G.; Milner, D.; Valentin, R.; Jackson, B.E.; Gordetsky, J.; West, J.; Rais-Bahrami, S.; Morgan, D.E. Quantitative iodine content threshold for discrimination of renal cell carcinomas using rapid kV-switching dual-energy CT. Abdominal Radiology 2017, 42, 727–734. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, S.; Radice, D.; Femia, M.; De Marco, P.; Origgi, D.; Preda, L.; Barberis, M.; Vigorito, R.; Mauri, G.; Mauro, A.; et al. Metastatic and non-metastatic lymph nodes: quantification and different distribution of iodine uptake assessed by dual-energy CT. European radiology 2018, 28, 760–769. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Luo, D.; Li, L.; Zhao, Y.; Lin, M.; Guo, W.; Zhou, C. Differentiation of malignant cervical lymphadenopathy by dual-energy CT: a preliminary analysis. Sci Rep 2016, 6, 31020–31020. [Google Scholar] [CrossRef]
- Sauter, A.P.; Ostmeier, S.; Nadjiri, J.; Deniffel, D.; Rummeny, E.J.; Pfeiffer, D. Iodine concentration of healthy lymph nodes of neck, axilla, and groin in dual-energy computed tomography. Acta radiologica (Stockholm, Sweden: 1987) 2020, 61, 1505–1511. [Google Scholar] [CrossRef]
Figure 1.
Flowchart of study inclusion.
Figure 2.
Exemplary demonstration of ROI measurements on iodine maps for A) the right sub-mandibular gland, B) a lymph node in cervical level II on the left side, C) the right jugular vein and D) the right lobe of the thyroid gland.
Figure 2.
Exemplary demonstration of ROI measurements on iodine maps for A) the right sub-mandibular gland, B) a lymph node in cervical level II on the left side, C) the right jugular vein and D) the right lobe of the thyroid gland.
Figure 3.
Absolute iodine values and normalized iodine ratios for the different organs and tissues of the head and neck.
Figure 3.
Absolute iodine values and normalized iodine ratios for the different organs and tissues of the head and neck.
Figure 4.
Column bars (mean with SD) of absolute iodine values for female vs male with p-values (green indicating significant differences).
Figure 4.
Column bars (mean with SD) of absolute iodine values for female vs male with p-values (green indicating significant differences).
Figure 5.
Column bars (mean with SD) of absolute iodine values for young vs middle-aged vs old subgroups.
Figure 5.
Column bars (mean with SD) of absolute iodine values for young vs middle-aged vs old subgroups.
Figure 6.
Column bars (mean with SD) of absolute iodine uptake for normal weight vs overweight vs obese subgroups.
Figure 6.
Column bars (mean with SD) of absolute iodine uptake for normal weight vs overweight vs obese subgroups.
Table 1.
Listing of the 35 ROI measurements with corresponding description of their placements.
| Structure | Number of ROI | ROI placement |
|---|---|---|
| Carotid artery | 2 | central within the vessel at the level of the thyroid gland |
| Jugular vein | 2 | central within the vessel at the level of the thyroid gland |
| Temporal lobe | 2 | right and left temporal lobe |
| Cerebellum | 2 | right and left cerebellum |
| Parotid glands | 2 | right and left gland, avoiding duct |
| Masseter muscle | 2 | the superficial portion on both sides |
| Uvula | 1 | distal of the soft palatine |
| Submandibular glands | 2 | right and left gland, avoiding duct |
| Sublingual glands | 2 | right and left gland, avoiding surrounding tissue |
| Palatine tonsils | 2 | at the most prominent portion |
| Tongue | 2 | right and left half of the tongue |
| Lingual tonsil | 1 | at the most prominent portion |
| Vocal cords | 2 | at the level of arytenoid cartilage |
| Thyroid gland | 4 | upper and lower portion both sides |
| Cervical lymph nodes | 5 | one on each cervical lymph node level |
| Sternocleidomastoid muscle | 2 | common muscle belly |
Table 2.
Absolute iodine concentration and normalized iodine ratio values for the different structures of the head and neck.
Table 2.
Absolute iodine concentration and normalized iodine ratio values for the different structures of the head and neck.
| Structure | Absolute iodine concentration in mg/ml (mean ± SD) |
Normalized iodine ratio |
|---|---|---|
| Carotid artery | 5.88 ± 2.0 | 1 |
| Jugular vein | 6.66 ± 2.7 | 1.29 ± 1.2 |
| Temporal lobe | 0.82 ± 0.4 | 0.17 ± 0.1 |
| Cerebellum | 1.41 ± 0.4 | 0.29 ± 0.2 |
| Parotid glands | 1.84 ± 0.8 | 0.36 ± 0.3 |
| Masseter muscle | 0.99 ± 0.4 | 0.21 ± 0.2 |
| Uvula | 1.90 ± 0.9 | 0.37 ± 0.3 |
| Submandibular glands | 2.37 ± 1.2 | 0.46 ± 0.4 |
| Sublingual glands | 3.41 ± 1.0 | 0.67 ± 0.5 |
| Palatine tonsils | 1.62 ± 0.7 | 0.33 ± 0.3 |
| Tongue | 1.45 ± 0.5 | 0.29 ± 0.2 |
| Lingual tonsil | 1.20 ± 0.5 | 0.23 ± 0.2 |
| Vocal cords | 2.18 ± 0.9 | 0.43 ± 0.4 |
| Thyroid gland | 4.68 ± 1.5 | 0.93 ± 0.9 |
| Cervical lymph nodes | 1.72 ± 1.0 | 0.35 ± 0.3 |
| Sternocleidomastoid muscle | 0.76 ± 0.3 | 0.15 ± 0.1 |
Table 3.
Absolute iodine concentration and normalized iodine ratio values for female vs male (asterisk indicates statistical significance).
Table 3.
Absolute iodine concentration and normalized iodine ratio values for female vs male (asterisk indicates statistical significance).
| Structure | Absolute iodine concentration in mg/ml (mean ± SD) |
p-values | |
| Female | Male | ||
| Carotid artery | 6.31 ± 2.1 | 5.66 ± 1.8 | <0.001* |
| Jugular vein | 7.56 ± 3.1 | 6.18 ± 2.3 | <0.001* |
| Temporal lobe | 0.86 ± 0.5 | 0.80 ± 0.3 | 0.199 |
| Cerebellum | 1.42 ± 0.3 | 1.42 ± 0.4 | 0.926 |
| Parotid glands | 2.00 ± 0.8 | 1.76 ± 0.7 | <0.001* |
| Masseter muscle | 1.06 ± 0.4 | 0.96 ± 0.4 | 0.003* |
| Uvula | 1.88 ± 1.0 | 1.91 ± 0.8 | 0.387 |
| Submandibular glands | 2.57 ± 1.3 | 2.27 ± 1.2 | 0.004* |
| Sublingual glands | 3.53 ± 1.0 | 3.35 ± 0.9 | 0.041* |
| Palatine tonsils | 1.74 ± 0.7 | 1.57 ± 0.6 | 0.018* |
| Tongue | 1.52 ± 0.5 | 1.41 ± 0.5 | 0.041* |
| Lingual tonsil | 1.25 ± 0.5 | 1.17 ± 0.4 | 0.078 |
| Vocal cords | 2.24 ± 0.9 | 2.14 ± 0.9 | 0.100 |
| Thyroid gland | 5.07 ± 1.6 | 4.48 ± 1.4 | <0.001* |
| Cervical lymph nodes | 1.83 ± 1.3 | 1.66 ± 0.8 | 0.053 |
| Sternocleidomastoid muscle | 0.87 ± 0.3 | 0.70 ± 0.3 | <0.001* |
| Structure | Normalized iodine ratios | p-values | |
| Female | Male | ||
| Jugular vein | 1.38 ± 1.3 | 1.24 ± 1.1 | 0.008* |
| Temporal lobe | 0.17 ± 0.2 | 0.17 ± 0.1 | 0.073 |
| Cerebellum | 0.27 ± 0.2 | 0.30 ± 0.3 | <0.001* |
| Parotid glands | 0.36 ± 0.2 | 0.37 ± 0.4 | 0.54 |
| Masseter muscle | 0.20 ± 0.2 | 0.21 ± 0.2 | 0.99 |
| Uvula | 0.34 ± 0.3 | 0.39 ± 0.3 | 0.001* |
| Submandibular glands | 0.46 ± 0.3 | 0.46 ± 0.4 | 0.53 |
| Sublingual glands | 0.65 ± 0.4 | 0.71 ± 0.6 | 0.049* |
| Palatine tonsils | 0.31 ± 0.2 | 0.34 ± 0.3 | 0.76 |
| Tongue | 0.29 ± 0.3 | 0.29 ± 0.2 | 0.48 |
| Lingual tonsil | 0.23 ± 0.1 | 0.24 ± 0.2 | 0.18 |
| Vocal cords | 0.41 ± 0.3 | 0.45 ± 0.5 | 0.35 |
| Thyroid gland | 0.94 ± 0.9 | 0.93 ± 0.9 | 0.72 |
| Cervical lymph nodes | 0.34 ± 0.3 | 0.36 ± 0.5 | 0.67 |
| Sternocleidomastoid muscle | 0.16 ± 0.1 | 0.15 ± 0.1 | 0.22 |
Table 4.
Absolute iodine concentration and normalized iodine ratio values for young vs middle-aged vs old subgroups (asterisk indicates statistical significance).
Table 4.
Absolute iodine concentration and normalized iodine ratio values for young vs middle-aged vs old subgroups (asterisk indicates statistical significance).
| Structure | Absolute iodine concentration in mg/ml (mean ± SD) |
p-values | ||||
|---|---|---|---|---|---|---|
| 18-48 years |
49-64 years |
65-98 years |
18-48 vs 49-64 | 18-48 vs 65-98 | 49-64 vs 65-98 | |
| Carotid artery | 5.48 ± 2.0 | 5.77 ± 1.7 | 6.39 ± 2.1 | 0.027* | <0.001* | 0.008* |
| Jugular vein | 5.75 ± 1.8 | 6.73 ± 2.6 | 7.48 ± 3.2 | <0.001* | <0.001* | 0.024* |
| Temporal lobe | 0.82 ± 0.3 | 0.85 ± 0.5 | 0.80 ± 0.3 | 0.69 | 0.74 | 0.45 |
| Cerebellum | 1.36 ± 0.4 | 1.45 ± 0.4 | 1.45 ± 0.3 | 0.032* | 0.022* | 0.93 |
| Parotid glands | 1.75 ± 0.7 | 1.92 ± 0.8 | 1.85 ± 0.8 | 0.099 | 0.86 | 0.86 |
| Masseter muscle | 1.06 ± 0.4 | 1.02 ± 0.4 | 0.91 ± 0.4 | 0.53 | <0.001* | 0.009* |
| Uvula | 1.83 ± 0.7 | 1.99 ± 0.9 | 1.87 ± 1.0 | 0.35 | 0.83 | 0.26 |
| Submandibular glands | 2.32 ± 1.1 | 2.44 ± 1.3 | 2.37 ± 1.3 | 0.39 | 0.93 | 0.54 |
| Sublingual glands | 3.34 ± 1.0 | 3.50 ± 0.9 | 3.40 ± 1.0 | 0.22 | 0.78 | 0.58 |
| Palatine tonsils | 1.74 ± 0.7 | 1.55 ± 0.7 | 1.57 ± 0.6 | 0.008* | 0.031* | 0.75 |
| Tongue | 1.65 ± 0.4 | 1.39 ± 0.5 | 1.29 ± 0.5 | <0.001 | <0.001 | 0.034 |
| Lingual tonsil | 1.24 ± 0.4 | 1.21 ± 0.4 | 1.13 ± 0.5 | 0.94 | 0.015* | 0.22 |
| Vocal cords | 2.01 ± 0.7 | 2.33 ± 1.0 | 2.19 ± 1.0 | 0.003* | 0.43 | 0.21 |
| Thyroid gland | 4.10 ± 1.2 | 4.79 ± 1.4 | 5.18 ± 1.7 | <0.001* | <0.001* | 0.01* |
| Cervical lymph nodes | 1.79 ± 1.2 | 1.75 ± 0.9 | 1.62 ± 0.9 | 0.75 | 0.53 | 0.31 |
| Sternocleidomastoid muscle | 0.71 ± 0.3 | 0.78 ± 0.3 | 0.78 ± 0.4 | 0.083 | 0.28 | 0.61 |
| Structure | Normalized iodine ratio (mean ± SD) |
p-values | ||||
|---|---|---|---|---|---|---|
| 18-48 years |
49-64 years |
65-98 years |
18-48 vs 49-64 | 18-48 vs 65-98 | 49-64 vs 65-98 | |
| Jugular vein | 1.27 ± 1.4 | 1.27 ± 0.9 | 1.32 ± 1.0 | 0.11 | 0.099 | 0.87 |
| Temporal lobe | 0.18 ± 0.2 | 0.17 ± 0.2 | 0.15 ± 0.1 | 0.54 | 0.004* | 0.023* |
| Cerebellum | 0.29 ± 0.2 | 0.30 ± 0.3 | 0.29 ± 0.4 | 0.75 | 0.034* | 0.077 |
| Parotid glands | 0.35 ± 0.2 | 0.37 ± 0.3 | 0.36 ± 0.4 | 0.92 | 0.03* | 0.023* |
| Masseter muscle | 0.22 ± 0.2 | 0.21 ± 0.2 | 0.18 ± 0.3 | 0.041* | <0.001* | 0.001* |
| Uvula | 0.38 ± 0.2 | 0.39 ± 0.4 | 0.34 ± 0.4 | 0.78 | 0.004* | 0.01* |
| Submandibular glands | 0.47 ± 0.3 | 0.47 ± 0.4 | 0.44 ± 0.4 | 0.52 | 0.038* | 0.21 |
| Sublingual glands | 0.68 ± 0.3 | 0.71 ± 0.7 | 0.66 ± 0.7 | 0.86 | <0.001* | 0.004* |
| Palatine tonsils | 0.35 ± 0.2 | 0.32 ± 0.3 | 0.33 ± 0.4 | <0.001* | <0.001* | 0.83 |
| Tongue | 0.36 ± 0.3 | 0.28 ± 0.2 | 0.23 ± 0.2 | <0.001* | <0.001* | <0.001* |
| Lingual tonsil | 0.26 ± 0.2 | 0.24 ± 0.2 | 0.21 ± 0.2 | 0.035* | <0.001* | 0.009* |
| Vocal cords | 0.43 ± 0.4 | 0.46 ± 0.4 | 0.42 ± 0.4 | 0.95 | 0.085 | 0.004* |
| Thyroid gland | 0.94 ± 1.2 | 0.92 ± 0.6 | 0.95 ± 0.9 | 0.035* | 0.12 | 0.69 |
| Cervical lymph nodes | 0.37 ± 0.3 | 0.36 ± 0.4 | 0.33 ± 0.5 | 0.91 | 0.001* | 0.033* |
| Sternocleidomastoid muscle | 0.15 ± 0.1 | 0.16 ± 0.1 | 0.14 ± 0.1 | 0.65 | 0.25 | 0.082 |
Table 5.
Absolute iodine concentration and normalized iodine ratio values for normal-weighted vs overweight vs obese subgroups (asterisk indicates statistical significance).
Table 5.
Absolute iodine concentration and normalized iodine ratio values for normal-weighted vs overweight vs obese subgroups (asterisk indicates statistical significance).
| Structure | Absolute iodine concentration in mg/ml (mean ± SD) |
p-values | ||||
|---|---|---|---|---|---|---|
| No BMI < 25 |
Ov 25 – 29.9 |
Ob BMI > 29.9 |
No vs Ov | No vs Ob | Ov vs Ob | |
| Carotid artery | 6.1 ± 2.0 | 5.84 ± 1.6 | 5.96 ± 2.0 | 0.91 | 0.59 | 0.84 |
| Jugular vein | 7.24 ± 2.7 | 6.37 ± 2.1 | 6.16 ± 2.5 | <0.001* | <0.001* | 0.87 |
| Temporal lobe | 0.83 ± 0.4 | 0.82 ± 0.3 | 0.83 ± 0.3 | 0.83 | 0.54 | 0.50 |
| Cerebellum | 1.44 ± 0.4 | 1.39 ± 0.3 | 1.45 ± 0.3 | 0.67 | 0.79 | 0.69 |
| Parotid glands | 2.10 ± 0.8 | 1.76 ± 0.7 | 1.46 ± 0.6 | <0.001* | <0.001* | 0.004* |
| Masseter muscle | 1.03 ± 0.4 | 0.98 ± 0.4 | 0.98 ± 0.3 | 0.22 | 0.60 | 0.79 |
| Uvula | 1.97 ± 1.0 | 1.91 ± 0.9 | 1.78 ± 0.7 | 0.56 | 0.51 | 0.39 |
| Submandibular glands | 2.59 ± 1.4 | 2.29 ± 1.1 | 2.26 ± 1.1 | 0.08 | 0.092 | 0.69 |
| Sublingual glands | 3.57 ± 1.0 | 3.33 ± 0.9 | 3.33 ± 0.9 | 0.014* | 0.024* | 0.87 |
| Palatine tonsils | 1.72 ± 0.7 | 1.61 ± 0.6 | 1.47 ± 0.6 | 0.29 | 0.014* | 0.29 |
| Tongue | 1.45 ± 0.5 | 1.48 ± 0.5 | 1.41 ± 0.5 | 0.83 | 0.63 | 0.53 |
| Lingual tonsil | 1.24 ± 0.5 | 1.21 ± 0.4 | 1.10 ± 0.4 | 0.58 | 0.006* | 0.038* |
| Vocal cords | 2.27 ± 0.9 | 2.14 ± 0.8 | 2.27 ± 1.2 | 0.40 | 0.40 | 0.80 |
| Thyroid gland | 4.99 ± 1.5 | 4.65 ± 1.5 | 4.41 ± 1.3 | 0.068 | 0.002* | 0.52 |
| Cervical lymph nodes | 1.85 ± 1.2 | 1.65 ± 0.8 | 1.64 ± 0.8 | 0.062 | 0.11 | 0.92 |
| Sternocleidomastoid muscle | 0.86 ± 0.4 | 0.70 ± 0.3 | 0.64 ± 0.3 | <0.001* | <0.001* | 0.64 |
| Structure | Normalized iodine ratio (mean ± SD) |
p-values | ||||
| No BMI < 25 |
Ov 25 – 29.9 |
Ob BMI > 29.9 |
No vs Ov | No vs Ob | Ov vs Ob | |
| Jugular vein | 1.39 ± 1.3 | 1.15 ± 0.6 | 1.26 ± 1.3 | 0.051 | 0.017* | 0.70 |
| Temporal lobe | 0.17 ± 0.2 | 0.16 ± 0.1 | 0.18 ± 0.2 | 0.48 | 0.36 | 0.85 |
| Cerebellum | 0.29 ± 0.3 | 0.27 ± 0.3 | 0.32 ± 0.3 | 0.73 | 0.23 | 0.53 |
| Parotid glands | 0.41 ± 0.4 | 0.34 ± 0.3 | 0.32 ± 0.3 | 0.003* | <0.001* | 0.69 |
| Masseter muscle | 0.20 ± 0.2 | 0.20 ± 0.3 | 0.22 ± 0.2 | 0.51 | 0.65 | 0.87 |
| Uvula | 0.39 ± 0.4 | 0.35 ± 0.2 | 0.37 ± 0.3 | 0.99 | 0.99 | 0.97 |
| Submandibular glands | 0.50 ± 0.4 | 0.41 ± 0.2 | 0.45 ± 0.4 | 0.37 | 0.16 | 0.63 |
| Sublingual glands | 0.69 ± 0.5 | 0.64 ± 0.6 | 0.72 ± 0.7 | 0.69 | 0.99 | 0.92 |
| Palatine tonsils | 0.34 ± 0.3 | 0.32 ± 0.4 | 0.33 ± 0.3 | 0.49 | 0.33 | 0.31 |
| Tongue | 0.29 ± 0.3 | 0.27 ± 0.1 | 0.31 ± 0.3 | 0.40 | 0.37 | 0.61 |
| Lingual tonsil | 0.23 ± 0.2 | 0.23 ± 0.1 | 0.24 ± 0.2 | 0.87 | 0.52 | 0.40 |
| Vocal cords | 0.44 ± 0.4 | 0.40 ± 0.3 | 0.46 ± 0.5 | 0.41 | 0.61 | 0.98 |
| Thyroid gland | 0.98 ± 0.9 | 0.87 ± 0.5 | 0.94 ± 0.9 | 0.43 | 0.71 | 0.74 |
| Cervical lymph nodes | 0.36 ± 0.4 | 0.33 ± 0.5 | 0.36 ± 0.4 | 0.34 | 0.75 | 0.75 |
| Sternocleidomastoid muscle | 0.17 ± 0.1 | 0.14 ± 0.1 | 0.14 ± 0.1 | 0.003* | 0.004* | 0.92 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
MDPI Initiatives
Important Links
© 2024 MDPI (Basel, Switzerland) unless otherwise stated